{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:22:08Z","timestamp":1786731728246,"version":"build-2736575974"},"reference-count":49,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Concurrent alcohol and opioid withdrawal syndrome is a common and challenging clinical scenario with little published evidence or guidance to inform pharmacotherapy strategies. Concurrent use of benzodiazepines and opioid agonists, which are considered first-line agents for management of each withdrawal syndrome independently, is controversial and often avoided in clinical practice. Strategies to provide effective, simultaneous medication treatment of alcohol and opioid withdrawal while optimizing patient safety are demonstrated through 3 patient cases.<\/jats:p>","DOI":"10.9740\/mhc.2023.12.268","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T14:58:22Z","timestamp":1701442702000},"page":"268-275","source":"Crossref","is-referenced-by-count":1,"title":["Concurrent opioid and alcohol withdrawal management"],"prefix":"10.9740","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5718-5013","authenticated-orcid":true,"given":"Michelle","family":"Colvard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"2023120114581688000_i2168-9709-13-6-268-b01","unstructured":"Center for Substance Abuse Treatment detoxification and substance abuse treatment.\n          \n          Treatment Improvement Protocol (TIP) Series, No. 45. HHS Publication No.(SMA) 15-4131.\nCenter for Substance Abuse Treatment,\n2006\n."},{"key":"2023120114581688000_i2168-9709-13-6-268-b02","article-title":"American Society of Addiction Medicine clinical practice guideline on alcohol withdrawal management","year":"2020"},{"key":"2023120114581688000_i2168-9709-13-6-268-b03","article-title":"American Society of Addiction Medicine national practice guideline for the treatment of opioid use disorder","year":"2020"},{"issue":"(4 Suppl)","key":"2023120114581688000_i2168-9709-13-6-268-b04","first-page":"5","article-title":"Treatment of patients with substance use disorders, second edition. American Psychiatric Association","volume":"164","author":"Kleber","year":"2007","journal-title":"Am J Psychiatry"},{"key":"2023120114581688000_i2168-9709-13-6-268-b05","article-title":"VA\/DoD clinical practice guideline for the management of substance use disorders","year":"2021"},{"issue":"(17)","key":"2023120114581688000_i2168-9709-13-6-268-b06","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1001\/jama.2022.4308","article-title":"Alcohol-related deaths during the COVID-19 pandemic","volume":"327","author":"White","year":"2022","journal-title":"JAMA"},{"key":"2023120114581688000_i2168-9709-13-6-268-b07","article-title":"Drug overdose deaths in the US top 100,000 annually","author":"Centers for Disease Control"},{"key":"2023120114581688000_i2168-9709-13-6-268-b08","doi-asserted-by":"crossref","first-page":"108886","DOI":"10.1016\/j.drugalcdep.2021.108886","article-title":"An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders","volume":"226","author":"Mintz","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2023120114581688000_i2168-9709-13-6-268-b09","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.drugalcdep.2018.12.030","article-title":"Co-occurring substance use and mental disorders among adults with opioid use disorder","volume":"197","author":"Jones","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"(2)","key":"2023120114581688000_i2168-9709-13-6-268-b10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jsat.2010.05.008","article-title":"Comparison of opiate-primary treatment seekers with and without alcohol use disorder","volume":"39","author":"Hartzler","year":"2010","journal-title":"J Subst Abus Treat"},{"issue":"(11)","key":"2023120114581688000_i2168-9709-13-6-268-b11","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br J Addict"},{"issue":"(2)","key":"2023120114581688000_i2168-9709-13-6-268-b12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The Clinical Opiate Withdrawal Scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoact Drugs"},{"issue":"(5)","key":"2023120114581688000_i2168-9709-13-6-268-b13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/alcalc\/agv043","article-title":"Prospective validation study of the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) in medically ill inpatients: a new scale for the prediction of complicated alcohol withdrawal syndrome","volume":"50","author":"Maldonado","year":"2015","journal-title":"Alcohol Alcohol"},{"issue":"(4)","key":"2023120114581688000_i2168-9709-13-6-268-b14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1080\/08897077.2017.1354119","article-title":"Development and implementation of an alcohol withdrawal protocol using a 5-item scale, the Brief Alcohol Withdrawal Scale (BAWS)","volume":"38","author":"Rastegar","year":"2017","journal-title":"Subst Abus"},{"issue":"(6)","key":"2023120114581688000_i2168-9709-13-6-268-b15","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s11606-019-04899-7","article-title":"Symptom-triggered therapy for alcohol withdrawal syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"34","author":"Holleck","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"(3)","key":"2023120114581688000_i2168-9709-13-6-268-b16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/alcalc\/agr020","article-title":"Alcohol withdrawal syndrome: symptom-triggered versus fixed-schedule treatment in an outpatient setting","volume":"46","author":"Elholm","year":"2011","journal-title":"Alcohol Alcohol"},{"issue":"(3)","key":"2023120114581688000_i2168-9709-13-6-268-b17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/alcalc\/agt181","article-title":"A comparative study of fixed tapering dose regimen versus symptom-triggered regimen of lorazepam for alcohol detoxification","volume":"49","author":"Sachdeva","year":"2014","journal-title":"Alcohol Alcohol"},{"issue":"(10)","key":"2023120114581688000_i2168-9709-13-6-268-b18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/archinte.162.10.1117","article-title":"Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial","volume":"162","author":"Daeppen","year":"2002","journal-title":"Arch Intern Med"},{"issue":"(7)","key":"2023120114581688000_i2168-9709-13-6-268-b19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jama.1994.03520070039035","article-title":"Individualized treatment for alcohol withdrawal: a randomized double-blind controlled trial","volume":"272","author":"Saitz","year":"1994","journal-title":"JAMA"},{"issue":"(6)","key":"2023120114581688000_i2168-9709-13-6-268-b20","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.genhosppsych.2012.06.016","article-title":"Benzodiazepine loading versus symptom-triggered treatment of alcohol withdrawal: a prospective, randomized clinical trial","volume":"34","author":"Maldonado","year":"2012","journal-title":"Gen Hosp Psychiatry"},{"issue":"(1-2)","key":"2023120114581688000_i2168-9709-13-6-268-b21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.drugalcdep.2009.07.001","article-title":"Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument","volume":"105","author":"Tompkins","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"2023120114581688000_i2168-9709-13-6-268-b22","article-title":"Title 21 Code of Federal Regulations 1306.07: Administering or dispensing of narcotic drugs. Available from","author":"US Drug Enforcement Administration Office of Diversion Control"},{"issue":"(2)","key":"2023120114581688000_i2168-9709-13-6-268-b23","article-title":"Managing opioid use disorder during and after acute hospitalization: a case-based review clarifying methadone regulation for acute care settings","volume":"4","author":"Noska","year":"2015","journal-title":"J Addict Behav Ther Rehabil"},{"issue":"(1)","key":"2023120114581688000_i2168-9709-13-6-268-b24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0376-8716(99)00027-7","article-title":"Predictors of discharges against medical advice from a short-term hospital detoxification unit","volume":"56","author":"Armenian","year":"1999","journal-title":"Drug Alcohol Depend"},{"issue":"(6)","key":"2023120114581688000_i2168-9709-13-6-268-b25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/ADM.0000000000000430","article-title":"Who leaves early? factors associated with against medical advice discharge during alcohol withdrawal treatment","volume":"12","author":"Pytell","year":"2018","journal-title":"J Addict Med"},{"key":"2023120114581688000_i2168-9709-13-6-268-b26"},{"key":"2023120114581688000_i2168-9709-13-6-268-b27","article-title":"FDA drug safety communications: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines","author":"Food and Drug Administration."},{"issue":"(2)","key":"2023120114581688000_i2168-9709-13-6-268-b28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amepre.2016.02.014","article-title":"Trends in the concomitant prescribing of opioids and benzodiazepines, 2002-2014","volume":"51","author":"Hwang","year":"2016","journal-title":"Am J Prev Med"},{"issue":"(4)","key":"2023120114581688000_i2168-9709-13-6-268-b29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.amepre.2015.03.040","article-title":"Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines","volume":"49","author":"Jones","year":"2015","journal-title":"Am J Prev Medicine"},{"key":"2023120114581688000_i2168-9709-13-6-268-b30","article-title":"VA\/DoD clinical practice guidelines for the use of opioids in the management of chronic pain","year":"2022"},{"issue":"(3)","key":"2023120114581688000_i2168-9709-13-6-268-b31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain \u2014 United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"Mmwr Recomm. Rep"},{"issue":"(6)","key":"2023120114581688000_i2168-9709-13-6-268-b32","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/pm\/pnaa475","article-title":"Impact of implementing an academic detailing program on opioid-benzodiazepine co-prescribing trends at the U.S. Department of Veterans Affairs","volume":"22","author":"Bounthavong","year":"2021","journal-title":"Pain Med"},{"key":"2023120114581688000_i2168-9709-13-6-268-b33","article-title":"Food and Drug Administration drug safety communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants","author":"Food and Drug Administration."},{"key":"2023120114581688000_i2168-9709-13-6-268-b34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.01.013","article-title":"Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment\u2014a nation-wide register-based open cohort study","volume":"174","author":"Abrahamsson","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"(5)","key":"2023120114581688000_i2168-9709-13-6-268-b35","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/add.14886","article-title":"Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine","volume":"115","author":"Park","year":"2020","journal-title":"Addiction"},{"key":"2023120114581688000_i2168-9709-13-6-268-b36","volume-title":"Medications for opioid use disorder","author":"Substance Abuse and Mental Health Services Administration","year":"2021"},{"issue":"(2)","key":"2023120114581688000_i2168-9709-13-6-268-b37","doi-asserted-by":"crossref","first-page":"e210061","DOI":"10.1001\/jamanetworkopen.2021.0061","article-title":"Association of opioid use disorder treatment with alcohol-related acute events","volume":"4","author":"Xu","year":"2021","journal-title":"Jama Netw Open"},{"issue":"(12)","key":"2023120114581688000_i2168-9709-13-6-268-b38","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1111\/acer.14729","article-title":"Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial","volume":"45","author":"Roache","year":"2021","journal-title":"Alcohol Clin Exp Res"},{"key":"2023120114581688000_i2168-9709-13-6-268-b39","author":"American Association of Psychiatric Pharmacists clinician guide for buprenorphine initiation"},{"key":"2023120114581688000_i2168-9709-13-6-268-b40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jcrc.2015.11.022","article-title":"Barbiturates for the treatment of alcohol withdrawal syndrome: a systematic review of clinical trials","volume":"32","author":"Mo","year":"2016","journal-title":"J Crit Care"},{"key":"2023120114581688000_i2168-9709-13-6-268-b41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajem.2020.12.074","article-title":"Treatment of opioid and alcohol withdrawal in a cohort of emergency department patients","volume":"43","author":"Mahmoud","year":"2021","journal-title":"Am J Emerg Med"},{"key":"2023120114581688000_i2168-9709-13-6-268-b42","article-title":"Phenobarbital tablet","author":"Chartwell Rx, LLC."},{"key":"2023120114581688000_i2168-9709-13-6-268-b43","article-title":"Tegretol (carbamazepine tablet)","author":"Novartis Pharmaceuticals Corporation."},{"key":"2023120114581688000_i2168-9709-13-6-268-b44","article-title":"Suboxone (Buprenorphine\/naloxone tablet)","author":"Reckitt Benckiser Pharmaceuticals, Inc."},{"key":"2023120114581688000_i2168-9709-13-6-268-b45","article-title":"Methadone tablet","author":"Cebert Pharmaceuticals, Inc."},{"issue":"(1)","key":"2023120114581688000_i2168-9709-13-6-268-b46","first-page":"86","article-title":"The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am","volume":"175","author":"Reus","year":"2018","journal-title":"J Psychiatry"},{"issue":"(5)","key":"2023120114581688000_i2168-9709-13-6-268-b47","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","article-title":"Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial","volume":"180","author":"Anton","year":"2020","journal-title":"Jama Intern Med"},{"issue":"(7)","key":"2023120114581688000_i2168-9709-13-6-268-b48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence","volume":"168","author":"Anton","year":"2011","journal-title":"AJP"},{"issue":"(7)","key":"2023120114581688000_i2168-9709-13-6-268-b49","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/14656566.2020.1732349","article-title":"Pharmacotherapeutic management of co-morbid alcohol and opioid use","volume":"21","author":"Hood","year":"2020","journal-title":"Expert Opin Pharmacother"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/13\/6\/268\/3296160\/i2168-9709-13-6-268.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/13\/6\/268\/3296160\/i2168-9709-13-6-268.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:23:31Z","timestamp":1731687811000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/13\/6\/article-p268.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,12,1]]},"published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2023.12.268","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}